The HBB Knockout HT29 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from HT29 human colon adenocarcinoma epithelial cells, featuring targeted disruption of the HBB gene. This heterogeneous knockout pool, generated without single-cell cloning, preserves polyclonal diversity while abolishing beta-globin expression. It provides a loss-of-function model for studying non-erythroid hemoglobin roles in a colon cancer context.
HT29 cells, established from a primary colon adenocarcinoma of a 44-year-old female, are a widely used in vitro intestinal epithelial model. They retain epithelial characteristics and are employed in studies of intestinal barrier function, differentiation, and cancer biology. Their relevance to colorectal carcinoma makes them a suitable host for interrogating gene function in this disease setting.
HBB encodes beta-globin, a subunit of hemoglobin A that transports oxygen in erythroid cells and may have non-erythroid functions. Beta-globin complexes with alpha-globin (HBA1/HBA2) and heme, and its expression is regulated by transcription factors GATA1, KLF1, and HIF1A downstream of erythropoietin signaling. Hemoglobin mediates oxygen delivery, nitric oxide metabolism, and reactive oxygen species scavenging, with interacting partners including alpha-hemoglobin stabilizing protein (AHSP) and haptoglobin. The heme biosynthetic pathway, involving ALAS2 and FECH, is critical for hemoglobin assembly. In HT29 cells, HBB knockout eliminates beta-globin, potentially impairing oxygen binding, nitric oxide handling, or redox homeostasis, and altering responses to hypoxia or oxidative stress.
While HBB??s role in colon cancer is not well defined, this knockout model permits investigation of non-erythroid hemoglobin function in intestinal epithelial carcinoma. Colon epithelial cells exist in a hypoxic environment, and hypoxia pathway dysregulation drives tumor progression. The polyclonal knockout cells allow dissection of beta-globin??s contribution to hypoxia adaptation, oxidative stress resilience, and nitric oxide signaling, and may shed light on hemoglobinopathy-related pathways in colon cancer.
Applications include exploring beta-globin??s impact on colon cancer hypoxia responses, oxidative stress, and nitric oxide metabolism via Western blotting, RT-qPCR, hemoglobin spectrophotometric assays, oxygen consumption measurements, and ROS detection. These cells also serve as a hemoglobinopathy model in a non-erythroid background, facilitating studies on genetic interactions and therapeutics. For more information, contact Ascent Research.
